The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BCAX stock, giving a Buy rating on January 22.Invest with ...

H.C. Wainwright raised the firm’s price target on Bicara Therapeutics (BCAX) to $45 from $42 and keeps a Buy rating on the shares after the ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...

在2025年，全球医药行业将见证一场为期长达数年的革命，涵盖肿瘤学、肥胖症治疗以及人工智能（AI）应用领域的重大突破。这些变化不仅会改变医疗行业的现状，还为患者提供了前所未有的希望与机会。 肿瘤学的未来：靶向突变与个性化疫苗 根据玛格丽特公主癌症中心的资深医生Lillian Siu的分析，我们正值肿瘤治疗的新时代，尤其是在靶向治疗的前沿——针对KRAS基因突变的药物正在迅速发展。第一代KRASG1 ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Home is more than a physical structure — it’s a place where people feel safe, seek comfort and connect with friends and ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

A West Virginia University legal scholar says current laws may be giving manufacturers of biologic drugs, like antibodies and ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.